Vimarsana
Biggest News Aggregation in the World

Page 2 - Comparative Effectiveness News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Comparative Effectiveness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Comparative Effectiveness Today - Breaking & Trending Today

Fracture Reduction Greater with Denosumab vs Zoledronic Acid - Vimarsana News

Fracture Reduction Greater with Denosumab vs Zoledronic Acid

In the absence of a randomized comparison trial on fracture risk reduction, researchers use negative control outcome to compare the two drugs.

Best Fat Burning Cream For Losing Weight 2023 - Vimarsana News

Best Fat Burning Cream For Losing Weight 2023

Looking for the best fat burning cream on the market? Read on to check out the best fat-burning creams for 2023.

Adjuvant Therapy For Early-Stage NSCLC After Surgery Yields Lower Costs - Vimarsana News

Adjuvant Therapy For Early-Stage NSCLC After Surgery Yields Lower Costs

Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.

Source: ajmc.com
Brain Aneurysm Foundation Announces 2023 Research Grants - Vimarsana News

Brain Aneurysm Foundation Announces 2023 Research Grants

/PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of...

Low achievement of guideline-recommended diabetes targets in Chinese adults - Vimarsana News

Low achievement of guideline-recommended diabetes targets in Chinese adults

1. In this cross-sectional study, the proportion of Chinese adults with self-reported type 2 diabetes who achieved a guideline-recommended HbA1c target was 64.1%. 2. The proportion of Chinse adults with self-reported type 2 diabetes who achieved a guideline-recommended blood pressure was 22.2%. Evidence Rating Level: 1 (Excellent) Study Rundown: More than one-quarter of the Chinese